Maxim Group assumed coverage on shares of Kairos Pharma (NYSEAMERICAN:KAPA – Get Free Report) in a research report issued to clients and investors on Thursday,Benzinga reports. The firm set a “buy” rating and a $4.00 price target on the stock. Maxim Group’s target price indicates a potential upside of 334.12% from the stock’s current price.
Separately, D. Boral Capital restated a “buy” rating and issued a $9.00 price target on shares of Kairos Pharma in a research report on Thursday, March 20th.
Read Our Latest Research Report on KAPA
Kairos Pharma Stock Down 5.0 %
About Kairos Pharma
We are a clinical-stage biopharmaceutical company advancing therapeutics for cancer patients that are designed to overcome key hurdles in immune suppression and drug resistance. These therapeutics include antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer and glioblastoma.
Further Reading
- Five stocks we like better than Kairos Pharma
- How to Profit From Growth Investing
- Why Dollar Tree’s Family Dollar Sale Could Spark a Comeback
- Why is the Ex-Dividend Date Significant to Investors?
- JPMorgan: The ‘NVIDIA of Banking’ Poised for More Gains?
- What is a Special Dividend?
- Buy the Chewy Stock Reversal? Here’s Why Now Is the Time
Receive News & Ratings for Kairos Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kairos Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
